Physician profile
Charles Willits
NPI 1154065134
$1,224.58
in general payments reported to CMS, 2019-2025
16 companies · $652 in 2025
The $652 reported for 2025 was more than what 79% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $116 · 2024: $456 · 2025: $652.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,225.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,224.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $221.39 | 2023-2025 | |
| Astrazeneca Pharmaceuticals Lp | $194.57 | 2023-2025 | Airsupra, Farxiga |
| Amgen INC. | $153.72 | 2025 | Otezla, Repatha, Krystexxa |
| Novo Nordisk INC | $134.99 | 2024-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $118.84 | 2024-2025 | |
| Glaxosmithkline, LLC. | $54.99 | 2023-2024 | Trelegy Ellipta, Arexvy |
| Takeda Pharmaceuticals U.S.A., INC. | $51.58 | 2023-2024 | Trintellix |
| Sumitomo Pharma America, INC. | $50.27 | 2023-2025 | Gemtesa |
| Otsuka America Pharmaceutical, INC. | $42.69 | 2024-2025 | Rexulti |
| Shield Therapeutics INC | $40.69 | 2024-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $38.66 | 2025 | Caplyta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $36.16 | 2023 | Spiriva Respimat, Stiolto Respimat |
| Viatris Specialty LLC | $31.48 | 2025 | Yupelri |
| Dexcom, INC. | $21.06 | 2024 | Dexcom G6 Transmitter |
| Boston Scientific Corporation | $19.52 | 2024 | Watchman Flx |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $13.97 | 2025 | Cologuard Collection Kit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Willits listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.